Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

被引:0
|
作者
Konno, Yosuke [1 ,2 ]
Mayama, Michinori [1 ,2 ,3 ]
Takehara, Kazuhiro [4 ]
Yokoyama, Yoshihito [5 ]
Suzuki, Jiro [6 ]
Susumu, Nobuyuki [7 ]
Harano, Kenichi [8 ]
Nakagawa, Satoshi [9 ]
Nakanishi, Toru [10 ]
Yamagami, Wataru [11 ]
Yoshihara, Kosuke [12 ]
Nomura, Hiroyuki [13 ]
Okamoto, Aikou [6 ]
Aoki, Daisuke [14 ,15 ]
Watari, Hidemichi [1 ,2 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, North 15,West 7,Kita ku, Sapporo 0608638, Japan
[2] Fac Med, North 15,West 7,Kita ku, Sapporo 0608638, Japan
[3] Univ Penn, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA USA
[4] NHO Shikoku Canc Ctr, Dept Gynecol Oncol, Matsuyama, Japan
[5] Hirosaki Univ, Grad Sch Med, Dept Obstet & Gynecol, Hirosaki, Japan
[6] Jikei Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan
[7] Int Univ Hlth & Welf, Dept Obstet & Gynecol, Narita, Japan
[8] Natl Canc Ctr Hosp East, Dept Med Oncol, Kashiwa, Japan
[9] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Osaka, Japan
[10] Tohoku Med & Pharmaceut Univ, Fac Med, Dept Obstet & Gynecol, Miyagi, Japan
[11] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan
[12] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Japan
[13] Tokai Univ, Sch Med, Dept Obstet & Gynecol, Isehara, Japan
[14] Sanno Med Ctr, Tokyo, Japan
[15] Int Univ Hlth & Welf, Grad Sch, Tokyo, Japan
关键词
Endometrial Neoplasms; Cohort Studies; Lymph Node Excision; Multivariate Analysis; PARAAORTIC LYMPHADENECTOMY; HIGH-RISK; STAGE-I; TRIAL; CARCINOMA;
D O I
10.3802/jgo.2025.36.e3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aimed to determine whether the number of resected pelvic lymph nodes (PLNs) affects the prognosis of endometrial cancer (EC) patients at post-operative risk of recurrence. Methods: JGOG2043 was a randomized controlled trial to assess the efficacy of three chemotherapeutic regimens as adjuvant therapy in EC patients with post-operative recurrent risk. A retrospective analysis was conducted on 250 patients who underwent pelvic lymphadenectomy alone in JGOG2043. The number of resected and positive nodes and other clinicopathologic risk factors for survival were retrieved. Results: There were 83 patients in the group with less than 20 PLNs removed (group A), while 167 patients had 20 or more PLNs removed (group B). There was no significant difference in patients' backgrounds between the two groups, and the rate of lymph node metastasis was not significantly different. There was a trend toward fewer pelvic recurrences in group B compared with group A (3.5% vs. 9.6%; p=0.050). Although Kaplan-Meier analysis showed no statistically significant difference in survival rates between the two groups (5-year overall survival [OS]=90.3%vs. 84.3%; p=0.199), multivariate analysis revealed that resection of 20 or more nodes is one of the independent prognostic factors (hazard ratio=0.49; 95% confidence interval=0.24-0.99; p=0.048), as well as surgical stage, high-risk histology, and advanced age for OS. Conclusion: Resection of 20 or more PLNs was associated with improved pelvic control and better survival outcomes in EC patients at risk of recurrence who underwent pelvic lymphadenectomy alone and were treated with adjuvant chemotherapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Prognostic impact of the number of metastatic lymph nodes in distal bile duct cancer: An analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery
    Ishihara, Shin
    Horiguchi, Akihiko
    Endo, Itaru
    Wakaki, Toshifumi
    Hirano, Satoshi
    Yamaue, Hiroki
    Yamamoto, Masakazu
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2020, 27 (07) : 396 - 401
  • [32] Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study
    Susumu, Nobuyuki
    Sagae, Satoru
    Udagawa, Yasuhiro
    Niwa, Kenji
    Kuramoto, Hiroyuki
    Satoh, Shinji
    Kudo, Ryuichi
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 226 - 233
  • [33] Impact of adjuvant treatments and risk factors on survival in 2023 FIGO stage IIB endometrial cancer patients: Turkish Gynecologic Oncology Group Study
    Akgor, Utku
    Basaran, Derman
    Meydanli, Mehmet Mutlu
    Kuscu, Esra
    Demirkiran, Fuat
    Topuz, Samet
    Sanci, Muzaffer
    Akbayir, Ozgur
    Gultekin, Murat
    Salihoglu, Mehmet Yavuz
    Akilli, Huseyin
    Bese, Tugan
    Firat, Zeliha
    Sozen, Hamdullah
    Ozgul, Nejat
    Ayhan, Ali
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [34] Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041)
    Nomura, H.
    Aoki, D.
    Takahashi, F.
    Katsumata, N.
    Watanabe, Y.
    Konishi, I.
    Jobo, T.
    Hatae, M.
    Hiura, M.
    Yaegashi, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study
    Garcia-Soto, Arlene E.
    Java, James J.
    Neira, Wilberto Nieves
    Pearson, J. Matthew
    Coh, David E.
    Lele, Shashikant B.
    Tewari, Krishnansu S.
    Walker, Joan L.
    Secord, Angeles Alvarez
    Armstrong, Deborah K.
    Copeland, Larry J.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 484 - 489
  • [36] Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
    Shoji, Tadahiro
    Enomoto, Takayuki
    Abe, Masakazu
    Okamoto, Aikou
    Nagasawa, Takayuki
    Oishi, Tetsuro
    Nagase, Satoru
    Mori, Masahiko
    Inokuchi, Yuki
    Kamiura, Shoji
    Komiyama, Shinichi
    Takeshima, Nobuhiro
    Sugiyama, Toru
    CANCER SCIENCE, 2022, 113 (01) : 240 - 250
  • [37] A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial)
    Sakai, Kensuke
    Yamagami, Wataru
    Sato, Yasunori
    Susumu, Nobuyuki
    Yokoyama, Yoshihito
    Takehara, Kazuhiro
    Mandai, Masaki
    Okamoto, Aikou
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [38] Prospective cohort study of bevacizumab plus standard platinum based chemotherapy as front-line treatment for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Japanese Gynecologic Oncology Group study (JGOG3022)
    Kato, K.
    Komiyama, S.
    Takeshima, N.
    Takano, H.
    Inoue, A.
    Hongo, A.
    Asai-Sato, M.
    Arakawa, A.
    Kubushiro, K.
    Kamiura, S.
    Sugiyama, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] The effect of anemia on the progression-free survival in epithelial ovarian cancer (stage II-IV) patients treated with paclitaxel-carboplatin combination therapy: a retrospective analysis of the JGOG3016 trial of the Japanese Gynecologic Oncology Group (JGOG3016-A)
    Sugiyama, T.
    Kumagai, S.
    Shouji, T.
    Michimae, H.
    Katsumata, N.
    Tsuda, H.
    Aoki, D.
    Terauchi, F.
    Jobo, T.
    Yasuda, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 456 - 456
  • [40] A Gynecologic Oncology Group study of frequent copy number aberrations in African American versus Caucasian women with stage I versus stage IIIC/IV endometrioid endometrial cancer
    Morrison, C.
    Gaile, D.
    Darcy, K.
    Liu, S.
    Shepherd, L.
    Cohn, D.
    McMeekin, S.
    Nowak, N.
    Maxwell, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)